Search Results
May 05, 2026, 03:48 ET GIGABYTE giành Giải thưởng Thiết kế Red Dot cho dòng sản phẩm AI
nâng cao. Các mẫu X870E AORUS XTREME X3D AI TOP, X870E AORUS MASTER X3D ICE và X870E AERO X3D WOOD đều được trang bị X3D Turbo Mode 2.0, một công nghệ ép xung AI động được huấn luyện dựa trên dữ liệu lớn để tự động điều chỉnh theo thời gian thực cho từng bộ vi xử lý. Hệ sinh thái AI này không chỉ
More news about: GIGABYTE
May 04, 2026, 09:05 ET Flex Completes Acquisition of Electrical Power Products (EP²)
Electrical Power Products, Inc. ("EP²"), a leading provider of engineered‑to‑order electrical power control and protection systems.EP² expands Flex's Critical Power offering, adding engineered‑to‑order capabilities that support
More news about: Flex
May 04, 2026, 06:00 ET CNA FINANCIAL ANNOUNCES FIRST QUARTER 2026 NET INCOME OF $0.78 PER SHARE AND CORE INCOME OF $0.83 PER SHARE
interest on corporate debt, and the results of certain property and casualty business in run-off, including asbestos and environmental pollution (A&EP), a legacy portfolio of excess workers' compensation (EWC) policies and legacy mass tort reserves.Financial MeasuresManagement
More news about: CNA Financial
May 04, 2026, 03:50 ET CS Analytical Announces Major Laboratory Expansion
raw materials testing, USP and EP gas qualification and the introduction of micro and biological testing it was imperative that additional laboratory space be secured and built out to
More news about: CS Analytical
May 01, 2026, 12:00 ET Boston Scientific Corporation (BSX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
alleges that, between July 23, 2025 and February 3, 2026, Defendants failed to disclose to investors that: (1) Boston Scientific's U.S. EP segment's growth rate was unsustainable and was approaching an earlier tipping point than the market was anticipating; (2) the Company was experiencing
More news about: Law Offices of Howard G. Smith
May 01, 2026, 09:55 ET BSX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Boston Scientific (BSX) Investors of Securities Class Action Deadline on May 4, 2026
disappointment in U.S. EP sales, and issued guidance for fiscal 2026 that fell well below expectations. The Company attributed its results and dismal guidance on a combination of slower than expected market growth alongside increased competition, despite management's previous claims of a "growing" EP business and
More news about: Faruqi & Faruqi, LLP
Apr 30, 2026, 09:00 ET BSX Investor Alert: BOSTON SCIENTIFIC CORPORATION Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Management Allegedly Misrepresented U.S. Electrophysiology Market Growth and Downplayed Competitive Pressures: SueWallSt
allegedly already materializing.As claimed in the action, management characterized the EP segment as "meaningfully large and rapidly expanding" and stated the Company would "continue to take share in the broad EP market" at the same time that the underlying growth trajectory was decelerating.The
More news about: SueWallSt.com
Apr 28, 2026, 12:00 ET Boston Scientific Corporation (BSX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
complaint filed alleges that, between July 23, 2025 and February 3, 2026, Defendants failed to disclose to investors that: (1) Boston Scientific's U.S. EP segment's growth rate was unsustainable and was approaching an earlier tipping point than the market was anticipating; (2) the Company was experiencing
More news about: The Law Offices of Frank R. Cruz, Los Angeles
Apr 28, 2026, 09:00 ET Lost Money on Boston Scientific Corporation (BSX)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm
disappointment in U.S. EP sales, and issued guidance for fiscal 2026 that fell well below expectations. The Company attributed its results and dismal guidance on a combination of slower than expected market growth alongside increased competition, despite management's previous claims of a "growing" EP business and
More news about: The Gross Law Firm
Apr 27, 2026, 12:00 ET Bronstein, Gewirtz & Grossman LLC Urges Boston Scientific Corporation Investors to Act: Class Action Filed Alleging Investor Harm
Scientific's projected growth rate for fiscal year 2025—particularly within its U.S. electrophysiology ("EP") segment—was not sustainable;Defendants' repeated statements expressing confidence in the U.S. EP division's growth trajectory, competitive positioning, and contribution to overall net income
More news about: Bronstein, Gewirtz & Grossman, LLC
Apr 25, 2026, 12:30 ET Medtronic announces key Affera™ clinical study milestones for Sphere-9™ and Sphere-360™ catheters as global adoption continues
2022; vol.15, no. 4.Cronin EM, et al. 2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias. EP Europace. 2019 Aug 1;21(8):1143-4.Zeppenfeld K, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the
More news about: Medtronic plc
Apr 25, 2026, 12:30 ET Abbott showcases strength of its technologies to address abnormal heart rhythms with late-breaking clinical data at Heart Rhythm Society 2026
https://www.cardiovascular.abbott/us/en/ep-clinical-evidence/volt-clinical-evidence.htmlTactiFlex™ Duo Ablation Catheter, Sensor Enabled™, AVEIR™ CSP Leadless Pacemaker System, and UltiSynq™
More news about: Abbott
Apr 24, 2026, 15:39 ET Boston Scientific Corporation (BSX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
alleges that, between July 23, 2025 and February 3, 2026, Defendants failed to disclose to investors that: (1) Boston Scientific's U.S. EP segment's growth rate was unsustainable and was approaching an earlier tipping point than the market was anticipating; (2) the Company was experiencing
More news about: Glancy Prongay Wolke & Rotter LLP
Apr 24, 2026, 02:02 ET German manufacturer infringes patent of Brazilian polyurethane breast implant technology - court grants Silimed preliminary injunction
manufacturing, distributing, and marketing polyurethane (PU) silicone breast implants in Germany using Silimed® patented technology according to European Patent EP 2 582 193 B1. Failure to comply will result in up to a 250,000 Euro for each breach by Polytech or up to six months of imprisonment, or up to two years
More news about: Silimed
Apr 24, 2026, 02:02 ET Deutscher Hersteller verletzt Patent auf brasilianische Technologie für Polyurethan-Brustimplantate - Gericht erlässt einstweilige Verfügung zugunsten von Silimed
(PU)-beschichteten Silikon-Brustimplantaten in Deutschland unter Verwendung der patentierten Technologie von Silimed® nach dem europäischen Patent EP 2 582 193 B1 mit sofortiger Wirkung einzustellen. Bei Nichtbeachtung drohen Polytech für jeden Verstoß ein Ordnungsgeld
More news about: Silimed
Apr 23, 2026, 09:00 ET BSX Investor Alert: BOSTON SCIENTIFIC CORPORATION Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Alleged Concealment of Electrophysiology Demand Weaknesses: SueWallSt
and adjusted EPS of $3.02 to $3.04 as late as October 22, 2025. The complaint asserts that these projections were issued while adverse trends in U.S. EP procedure volumes, competitive dynamics, and reimbursement headwinds were already affecting the segment's trajectory."Institutional investors
More news about: SueWallSt.com
Apr 23, 2026, 08:00 ET Immunic, Inc. Announces 1-for-10 Reverse Stock Split
split-adjusted basis at the opening of the Nasdaq Capital Market on April 27, 2026. The new CUSIP number for the split-adjusted common stock will be 4525EP200.At the Company's special meeting of stockholders on April 14, 2026, the stockholders approved a proposal to amend the Company's certificate
More news about: Immunic, Inc.
Apr 22, 2026, 09:00 ET BSX Investor Alert: BOSTON SCIENTIFIC CORPORATION Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Misrepresenting Electrophysiology Procedure Growth: Levi & Korsinsky
During the accompanying earnings call, management described 94% EP sales growth and characterized the quarter as "exceptional top-line performance." The lawsuit contends that management projected "continued high single-digit growth" in EP for the second half of 2025 while allegedly aware
More news about: Levi & Korsinsky, LLP
Apr 21, 2026, 20:53 ET Kelun-Biotech Announces Three Clinical Study Results Selected for Oral Presentations at 2026 ASCO Annual Meeting
are sponsored and led by MSD.About A400/EP0031A400/EP0031 novel next-generation selective RET inhibitor for NSCLC, medullary thyroid cancer (MTC) and other solid tumors with a high prevalence of RET alterations. The NDA of A400/EP0031 has been accepted for review by the Center
More news about: Kelun-Biotech
Apr 21, 2026, 20:28 ET 2026 ASCO | 科倫博泰3項研究成果入選2026美國臨床腫瘤學會年會口頭彙報
科倫博泰生物醫藥股份有限公司(「科倫博泰」或「公司」，6990.HK)將在本次大會公佈TROP2 ADC蘆康沙妥珠單抗(sac-TMT，佳泰萊®)、下一代選擇性RET抑制劑富馬酸侖博替尼(A400/EP0031，寧泰萊®[1])以及新型ADC SKB500的三項臨床研究結果，相關研究摘要全文將於當地時間2026年5月21日發佈在 ASCO
More news about: 科倫博泰
Apr 21, 2026, 09:50 ET BSX INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Boston Scientific (BSX) Investors of Securities Class Action Deadline on May 4, 2026
disappointment in U.S. EP sales, and issued guidance for fiscal 2026 that fell well below expectations. The Company attributed its results and dismal guidance on a combination of slower than expected market growth alongside increased competition, despite management's previous claims of a "growing" EP business and
More news about: Faruqi & Faruqi, LLP
Apr 21, 2026, 09:00 ET BSX Shareholder Alert: May 4, 2026 Lead Plaintiff Deadline in Boston Scientific Corporation Securities Class Action Lawsuit -- The Gross Law Firm
disappointment in U.S. EP sales, and issued guidance for fiscal 2026 that fell well below expectations. The Company attributed its results and dismal guidance on a combination of slower than expected market growth alongside increased competition, despite management's previous claims of a "growing" EP business and
More news about: The Gross Law Firm
Apr 21, 2026, 07:00 ET Corify Care Validates 4-D Global Cardiac Mapping for Complex Atrial and Ventricular Arrhythmias
instantly, the ACORYS® mapping system provides actionable insight before ablation begins."Time and predictability are the most valuable assets in the EP lab," said Andreu Climent, PhD, CEO of Corify Care. "These publications prove that we can give physicians the full picture upfront, without delay.
More news about: Corify Care
Apr 21, 2026, 06:00 ET LUMA Vision to Showcase VERAFEYE 4D Imaging Platform at HRS 2026, Signaling a New Foundation for EP Guidance
seconds, supporting faster, more intuitive, and more precise procedures.VERAEYE is redefining EP Guidance — from tools to platform, VERAFEYE is designed to eliminate the fragmentation of current EP workflows by enabling physicians to see and guide therapy in real time, rather than relying on the
More news about: LUMA Vision
Apr 20, 2026, 16:45 ET CHAGEE Partners with Laufey as Brand Accelerates U.S. Expansion
between Reykjavik and Washington, D.C., she learned piano and cello as a child, later studying at Berklee College of Music. There, she wrote her debut EP, 2021's Typical of Me, whose striking single "Street by Street" debuted at #1 on Icelandic radio—the first of many achievements that have grown
More news about: CHAGEE